title: Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats.
abstract: Basic fibroblast growth factor (bFGF) stimulates angiogenesis and induces neural cell regeneration. We investigated the effects of bFGF on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetic rats were treated with human recombinant bFGF as follows: 1) intravenous administration, 2) intramuscular injection into thigh and soleus muscles with cross-linked gelatin hydrogel (CGH), and 3) intramuscular injection with saline. Ten or 30 days later, the motor nerve conduction velocity (MNCV) of the sciatic-tibial and caudal nerves, sensitivity to mechanical stimuli, sciatic nerve blood flow (SNBF), and retinal blood flow (RBF) were measured. Delayed MNCV in the sciatic-tibial and caudal nerves, hypoalgesia, and reduced SNBF in diabetic rats were all ameliorated by intravenous administration of bFGF after 10, but not 30, days. Intramuscular injection of bFGF with CGH also improved sciatic-tibial MNCV, hypoalgesia, and SNBF after 10 and 30 days, but caudal MNCV was not improved. However, intramuscular injection of bFGF with saline had no significant effects. bFGF did not significantly alter RBF in either normal or diabetic rats. These observations suggest that bFGF could have therapeutic value for diabetic neuropathy and that CGH could play important roles as a carrier of bFGF.
authors.affiliation: Division of Metabolic Diseases, Department of Internal Medicine, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.
authors.forename: Mika
authors.initials: M
authors.lastname: Nakae
authors.forename: Hideki
authors.initials: H
authors.lastname: Kamiya
authors.forename: Keiko
authors.initials: K
authors.lastname: Naruse
authors.forename: Naoichi
authors.initials: N
authors.lastname: Horio
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Ito
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Mizubayashi
authors.forename: Yoji
authors.initials: Y
authors.lastname: Hamada
authors.forename: Eitaro
authors.initials: E
authors.lastname: Nakashima
authors.forename: Noboru
authors.initials: N
authors.lastname: Akiyama
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Atsuko
authors.initials: A
authors.lastname: Watarai
authors.forename: Nachi
authors.initials: N
authors.lastname: Kimura
authors.forename: Masayuki
authors.initials: M
authors.lastname: Horiguchi
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tabata
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Oiso
authors.forename: Jiro
authors.initials: J
authors.lastname: Nakamura
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D003432:Cross-Linking Reagents; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D003929:Diabetic Neuropathies / Q000517:prevention & control*; D004338:Drug Combinations; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000627:therapeutic use*; D005780:Gelatin / Q000008:administration & dosage; D007273:Injections, Intramuscular; D008297:Male; D009431:Neural Conduction / Q000187:drug effects; D011099:Polyglutamic Acid / Q000008:administration & dosage; D051381:Rats; D017208:Rats, Wistar; D012171:Retinal Vessels / Q000187:drug effects / Q000503:physiopathology
chemical_list: D043925:Angiogenesis Inducing Agents; D003432:Cross-Linking Reagents; D004338:Drug Combinations; C101913:gelatin-polyglutamic acid glue; D016222:Fibroblast Growth Factor 2; D011099:Polyglutamic Acid; D005780:Gelatin